Remove Drug Pricing Remove Packaging Remove Pharmaceutical Companies
article thumbnail

STAT+: Congress’s PBM reforms won’t end America’s drug pricing woes. Here’s what they would do

STAT

They’re focused this summer on reining in pharmacy middlemen to make the system fairer — but none of their many proposals will actually tackle the core dynamic that has incentivized higher drug prices. There are major packages on so-called PBM reform percolating in at least six different congressional committees.

article thumbnail

STAT+: Warren urges FTC to probe deal that would give Novo Nordisk control of some Catalent plants

STAT

billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer, over concerns the acquisition would give the pharmaceutical company an unfair advantage in the burgeoning market for drugs used to treat obesity and diabetes.

Packaging 297
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

Warnings for Japanese pharmaceutical market may lead to more lenient price controls

Pharmaceutical Technology

Based on GlobalData estimates, the Japanese pharmaceutical market generated JPY9.392 trillion ($67.32 However, despite this significant market share, the Japanese market is likely to become a less attractive market for international pharmaceutical companies based on recent findings from the Office of Pharmaceutical Industry Research (OPIR).

article thumbnail

STAT+: Pharmalittle: We’re reading about Congress reining in PBMs, Sanofi suing HHS, and more

STAT

Lawmakers agreed to extend telehealth flexibilities, fund public health programs, and enact these major changes as part of a government funding package they are planning to pass before the end of the year. The language of the government funding package has not been publicly released, and could still change. The move came after the U.S.

Packaging 132
article thumbnail

How early planning leads to successful market access and drug launch in Europe

Pharmaceutical Technology

An example is NICE’s Quality Adjusted Life Year score, used to price drugs in the UK. Some nations such as France base their decisions on the drug’s medical benefit and clinical added value versus existing therapies. Overall, it is never too soon to begin market access activities, but it can easily be too late.

article thumbnail

Biden administration – What can the healthcare industry expect?

pharmaphorum

We don’t believe there will be draconian price cuts, for the same reason. The Biden administration could put additional scrutiny on drug prices, but more drastic measures, such as allowing Medicare to negotiate with pharma companies directly, are still unlikely.”.